Sigma-Aldrich — Investor Presentation (June 2013)
28 slides from Sigma-Aldrich's investor presentation, Jun 3, 2013
Slide 1: Sigma-Aldrich Corporation June 2013 Investor Information
© 2013 Sigma-Aldrich Co. All rights reserved. Sigma-Aldrich Corporation •June 2013 Investor Information
Slide 2: Cautionary Statements
© 2013 Sigma-Aldrich Co. All rights reserved. 2 Cautionary Statements • This presentation contains “forward-looking statements” regarding future sales, earnings, return on invested capital, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions, div
Slide 3: Our Purpose: Enabling Science to Improve the Quality of Life
© 2013 Sigma-Aldrich Co. All rights reserved. Our Purpose 3 Enabling Science to Improve the Quality of Life PHARMA & ELECTRONICS MANUFACTURING RESEARCH LABS DIAGNOSTIC & TESTING LABS INDUSTRIAL MARKETS MARKETS:
Slide 4: Sigma-Aldrich in 2012
© 2013 Sigma-Aldrich Co. All rights reserved. Sigma-Aldrich in 2012 GLOBALLY BALANCED 43% Total Americas 37% Europe, Middle East, Africa 20% Asia Pacific 43% 37% 20% $2.6 Billion 53% 24% 23% 21% 79% BROAD END-MARKETS 53% Research 23% Applied 24% SAFC Commercial QUALITY PRODUCTS >170,000 Reagents and
Slide 5: Market Focused Business Units
© 2013 Sigma-Aldrich Co. All rights reserved. APPLIED Market Focused Business Units 5 RESEARCH Reagents, Consumables, Kits, Workflow Solutions for Life Sciences and Industrial Research Customized Manufacturing and Services for Commercial Products in Life Sciences and Electronics Raw Materials and So
Slide 6: Research Business Unit
© 2013 Sigma-Aldrich Co. All rights reserved. RESEARCH Business Unit 6 53% Customer Focus • Academic • Pharma • Dealers Our Strategy • Innovate Solutions • Broaden Portfolio • Expand Geographic and Channel Reach % of 2012 overall sales
Slide 7: Chemical Synthesis Workflow
© 2013 Sigma-Aldrich Co. All rights reserved. Chemical Synthesis Workflow 7 Planning and Preparation Synthesis and Manufacturing Purification and Characterization • Catalysts • Monomers • Specialty synthesis products • LC and GC columns • Sample collection and preparation • Reference standards • DNA
Slide 8: Life Science Workflow
© 2013 Sigma-Aldrich Co. All rights reserved. Life Science Workflow DNA & RNA Proteins & Small Molecules Cells & Organisms • Protein depletion technology • SPME devices • LC and GC columns • LOPAC® small molecule library • Validated antibodies Products & Services for RESEARCH: • Reporter cell lines
Slide 9: SAFC Commercial Business Unit
© 2013 Sigma-Aldrich Co. All rights reserved. SAFC COMMERCIAL Business Unit 9 24% Customer Focus • Life Science Products • Life Science Services • Hitech Electronics Our Strategy • Intense Focus on Top “100” Customers • Increase Capacity to Meet Market Demand • Add Strategic Capabilities to Meet Dev
Slide 10: SAFC Commercial Business Unit Segments
© 2013 Sigma-Aldrich Co. All rights reserved. Business Unit Segments Business Unit Initiatives Description 2012 SAFC Sales Customer Markets Biological Drugs Small Molecule Drugs LEDs Semiconductors Energy/Display Life Science Products Biopharma Materials Critical raw materials for biological drugs ~
Slide 11: Applied Business Unit
© 2013 Sigma-Aldrich Co. All rights reserved. 11 23% APPLIED Business Unit Customer Focus • Diagnostics/Testing • Industrial Applications Our Strategy • Engage and Expand Applied Customer Base • Develop Solutions Tailored to Customer Applications • Broaden Our Capabilities – Organic and Inorganic %
Slide 12: Applied Workflow
© 2013 Sigma-Aldrich Co. All rights reserved. Applied Workflow 12 Sample Prep Detection Analysis • Reference standards • Oligonucleotides • LC and GC columns Products & Services Sigma-Aldrich Offers: • LC and GC columns • Reference standards • Protein depletion technology • Sampling devices • DNA/RN
Slide 13: Industrial Applications
© 2013 Sigma-Aldrich Co. All rights reserved. Industrial Applications • Specialty Chemicals • Petrochemicals • Healthcare, Med Device, Contact Lenses Focus Areas: • Agricultural Products • Food Processing • Broad Chemical Offer • Bench-to-Bulk Capabilities • Custom Manufacturing • Amplification Buff
Slide 14: Focusing on Where Our Customers are Going
© 2013 Sigma-Aldrich Co. All rights reserved. Focusing on Where Our Customers are Going • Sales in ~160 countries • 103,000+ accounts • 1.4 million individual customers • Over 50 offices in 30 countries • Inventory staged within a day for >90% of customers • Working with customers to integrate their
Slide 15: Q1 2013 Results
© 2013 Sigma-Aldrich Co. All rights reserved. Q1 2013 Results
Slide 16: Q1 2013 Highlights
© 2013 Sigma-Aldrich Co. All rights reserved. • Record quarterly sales and EPS • Positive traction in new organization • Improving trends in Pharma • Research Pharma returning to growth • Commercial Pharma continuing strong growth trajectory • Academic business declined low single digits (adjusted f
Slide 17: First Quarter 2013 Financial Results
© 2013 Sigma-Aldrich Co. All rights reserved. (1) See Slide 28 for Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow. (2) Special items include acquisition transaction costs. 17 First Quarter 2013 Financial Results ($ in millions, except per share amounts) YEAR-OVER-YEAR
Slide 18: First Quarter 2013 Sales Growth Reconciliation
© 2013 Sigma-Aldrich Co. All rights reserved. 18 First Quarter 2013 Sales Growth Reconciliation 2013 Q1 Overall Organic Sales Growth of 1% Applied Q1 3 % (1)% 2 % 4 % Research Q1 (1) % (2)% - % (3)% Total Customer Sales Q1 1 % (1)% 2 % 2 % Sales Growth Organic FX Acquisitions Reported SAFC Commercia
Slide 19: 2013 Q1 Organic Sales Performance Highlights
© 2013 Sigma-Aldrich Co. All rights reserved. 19 2013 Q1 Organic Sales Performance Highlight vs. PY Q1 Business Unit: Research: Academic/Govt/Hospitals (Mid-single digit) Pharma Flat Dealers Low-to-mid single digit Applied Diagnostics/Testing High-single digit Industrial (Low-single digit) SAFC Comm
Slide 20: 2013 Guidance
© 2013 Sigma-Aldrich Co. All rights reserved. 20 2013 Guidance Organic Sales Growth 2013 full-year adjusted EPS expected to be in a range of $4.10 to $4.20 1st Half 2nd Half Full Year Research Low-single digit Low-single digit Low-to-mid single digit Applied Mid-single digit Mid-single digit SAFC Co
Slide 21: Proven Formula for Value Creation
© 2013 Sigma-Aldrich Co. All rights reserved. Proven Formula for Value Creation 2 ,6 2 3 2 ,2 0 1 2 ,5 0 5 +5% CAGR 2012 2007 2 ,0 3 9 2 ,2 7 1 2 ,1 4 8 25.125.824.323.222.922.5 2012 2007 20.1 23.222.4 19.818.717.9 2012 2007 Sales Growth Strong ROIC GAAP Margin Expansion Peers: Life Technologies, Qi
Slide 22: Q1 2013 Earnings Review Questions?
© 2013 Sigma-Aldrich Co. All rights reserved. Sigma-Aldrich Corporation Q1 2013 Earnings Review Questions?
Slide 23: Appendix: Reconciliation of GAAP to Non-GAAP Financial Measures
© 2013 Sigma-Aldrich Co. All rights reserved. Appendix •Reconciliation of GAAP to Non-GAAP Financial Measures
Slide 24: Reconciliation of Net Income and Diluted EPS to Adjusted
© 2013 Sigma-Aldrich Co. All rights reserved. 2013 2012 2013 2012 Reported net income 122$ 117$ $1.01 $0.96 Acquisition transaction costs — 4 — 0.03 Adjusted net income 122$ 121$ $1.01 $0.99 Three Months Ended Three Months Ended March 31, March 31, Net Income Diluted Earnings (in millions) Per Share
Slide 25: Reconciliation of Reported Operating Income to Adjusted
© 2013 Sigma-Aldrich Co. All rights reserved. Reconciliation of Reported Operating Income to Adjusted Operating Income (Unaudited) 25 2013 2012 Reported operating income 166$ 172$ Acquisition transaction costs — 5 Adjusted operating income 166$ 177$ Three Months Ended March 31, In millions
Slide 26: Reconciliation of Operating Income Margin to Adjusted
© 2013 Sigma-Aldrich Co. All rights reserved. 26 March 31, December 31, September 30, June 30, 2013 2012 2012 2012 Reported O perating Income Margin 24.6% 25.0% 24.4% 25.2% Restructuring cost —% 0.2% 0.6% 0.6% Adjusted O perating Income Margin 24.6% 25.2% 25.0% 25.8% Three Months Ended Reconciliatio
Slide 27: Reconciliation of Reported EPS to Adjusted EPS
© 2013 Sigma-Aldrich Co. All rights reserved. Reconciliation of Reported Earnings Per Share to Adjusted Earnings Per Share (Unaudited) 27 2013 2012 Reported Earnings Per Share 1.01$ 0.96$ Currency 0.02 n/a Adjusted Earnings Per Share 1.03$ 0.96$ March 31, Three Months Ended
Slide 28: Reconciliation of Operating Cash Flow to Free Cash Flow
© 2013 Sigma-Aldrich Co. All rights reserved. Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Unaudited) 28 2013 2012 Net cash provided by operating activities 154$ 144$ Less: Capital expenditures (25) (32) Free cash flow 129$ 112$ March 31, Three Months Ended In milli